Genmab A/S (GNMSF) Liabilities and Shareholders Equity (2019 - 2026)

Genmab A (GNMSF) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $12.4 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 87.91% year-over-year to $12.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.7 billion (up 197.95% YoY) and the FY2025 annual result came in at $12.9 billion, up 100.7% from the prior year.
• Liabilities and Shareholders Equity eased to $12.4 billion in Q1 2026, from $12.9 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $12.9 billion in Q4 2025 to a low of $5.2 billion in Q4 2023.
• A 4-year average of $8.1 billion and a median of $6.6 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity increased 22.59% — and 2025, when it surged 100.7%.
• Tracing GNMSF's Liabilities and Shareholders Equity over 4 years: stood at $5.2 billion in 2023, then increased by 22.59% to $6.4 billion in 2024, then jumped by 100.7% to $12.9 billion in 2025, then slipped by 3.86% to $12.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $12.4 billion (Q1 2026), $12.9 billion (Q4 2025), and $7.0 billion (Q3 2025), per Business Quant data.